MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/157489106777452638

Медицинская библиотека · Recent patents on anti-infective drug discovery · 2006

Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides.

Melo Manuel N, Dugourd Dominique, Castanho Miguel A R B

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Ribosomally synthesized antimicrobial peptides have very wide killing spectra and bacterial resistance to these peptides seems to be a rare phenomenon. Indolicidin is a ribosomally synthesized antimicrobial peptide that served as a template to omiganan, which is in development for the prevention of catheter-related bloodstream infections; clinical trials also proved its efficiency against acne vulgaris. Omiganan is the most advanced molecule in the front line of clinical applications of antimicrobial peptides. The mode and site of action of omiganan are not yet settled although its interaction with membranes is known to play a fundamental role. The biochemical and biophysical foundations for the action of indolicidin and its analogues are reviewed in this paper, as well as the clinical application of omiganan. The in vitro efficiency tests and the outcome of clinical trials are addressed. Altogether, despite the very specific use of omiganan as a topical antibiotic, it has the potential of being a pioneer of a new generation of antibiotics that carry the promise of ending the multi-resistance problem.

Для цитирования: Melo Manuel N, Dugourd Dominique, Castanho Miguel A R B. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides.. Recent patents on anti-infective drug discovery. 2006. DOI: 10.2174/157489106777452638.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.